Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2018 | Promising POUT: perioperative chemotherapy for upper tract urothelial cancer

Robert Jones • 8 Feb 2018
GU Cancers 2018
Bladder Cancer Genitourinary Cancer
POUT

The UK was well represented at the Genitourinary Cancers Symposium 2018, held in San Francisco, CA. In this video, Robert Jones, PhD, of the University of Glasgow & Beatson West of Scotland Cancer Centre, Glasgow, UK, discusses the Phase III Peri-Operative Chemotherapy Versus sUrveillance in Upper Tract Urothelial Cancer trial (POUT; NCT01993979). Prof. Jones emphasizes the importance of this trial, in both the type of cancer studied and the practice-changing potential of the results.

More from Robert Jones

Novel AR-targeted therapies in prostate cancer: CYP11A1 inhibitors, AR degraders and RIPTACs
4:43
Novel AR-targeted therapies in prostate cancer: CYP11A1 inhibitors, AR degraders and RIPTACs
Robert Jones • 25 Oct 2026
ESMO 2026 updates in MIBC: TROPHY-U-01, KEYNOTE-866 and ENERGIZE
5:54
ESMO 2026 updates in MIBC: TROPHY-U-01, KEYNOTE-866 and ENERGIZE
Robert Jones • 25 Oct 2026
Areas of unmet need in metastatic urothelial carcinoma
2:04
Areas of unmet need in metastatic urothelial carcinoma
Robert Jones • 4 Jun 2022
ASCO 2022: genitourinary cancer highlights
1:10
ASCO 2022: genitourinary cancer highlights
Robert Jones • 4 Jun 2022

Related Videos

Decipher score predicts metastasis risk and abiraterone benefit in prostate cancer
1:55
Decipher score predicts metastasis risk and abiraterone benefit in prostate cancer
Sarah Howlett • 26 Oct 2026
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
2:20
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
Jens Bedke • 26 Oct 2026
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
2:24
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
Jens Bedke • 26 Oct 2026
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
2:58
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
Jens Bedke • 26 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals